Browse the evidence

Chronic ingestion of a western diet (high glucose and free fatty acids) causes endothelial stress and platelet hyperactivity, which precedes and drives systemic metabolic inflammation and insulin resistance.

Focus on the quality and combination of your meals rather than just calorie counting or sugar avoidance. High-fat and high-carb meals can both trigger acute blood vessel stress. Prioritize whole foods that minimize rapid spikes in blood glucose and free fatty acids to protect your endothelial health and prevent the inflammation that leads to insulin resistance.

Pioglitazone (PPAR-gamma agonist) improves histological features of NASH but is limited by problematic weight gain and is not widely adopted.

Pioglitazone can improve liver histology in NASH patients (34% vs 19% placebo), but it causes weight gain and is not widely used. It is considered only when lifestyle changes fail and other options are not suitable.

Sarcopenia is mechanistically driven by mitochondrial bioenergetic dysfunction, characterized by downregulated PGC-1α/ERRα signaling, reduced oxidative phosphorylation, and low NAD+ levels, rather than primarily by inflammation or denervation.

This research highlights that muscle loss in older adults is fundamentally linked to mitochondrial energy failure and low NAD+ levels, distinct from general inflammation or nerve issues. While this paper does not prescribe a specific exercise or supplement protocol, it strongly suggests that interventions aiming to boost mitochondrial function (e.g., through exercise which stimulates PGC-1α, or potential NAD+ precursors) may be more effective for treating pathological sarcopenia than approaches focused solely on protein intake or anti-inflammatories.

Chronic senescence, driven by accumulated cellular stress and defective clearance mechanisms, is a primary driver of biological aging and age-related diseases, whereas acute senescence serves beneficial roles in development and tissue repair.

Aging is not just 'wear and tear' but involves specific cells (senescent cells) that stop dividing but secrete inflammatory factors (SASP) that damage surrounding tissue. As we age, our immune system becomes less efficient at clearing these cells, leading to accumulation and disease. Current research focuses on 'senolytics' (drugs that kill these cells) to potentially improve health in the elderly, though no universally accepted biomarker or treatment is yet standard.

In the presence of a high-fat diet, fructose supplementation causes pronounced obesity, glucose intolerance, and hepatic insulin resistance, whereas glucose supplementation does not cause these metabolic deficits despite similar caloric intake.

If you are eating a high-fat diet, the type of sugar you consume matters significantly. Fructose (found in high-fructose corn syrup and table sugar) promotes obesity and insulin resistance, whereas glucose does not have the same negative impact on insulin signaling under these conditions. To mitigate metabolic risk, prioritize reducing fructose intake, especially when dietary fat is high.

Fructose uniquely upregulates the transcription factor SREBP1c and downstream fatty acid synthesis genes, leading to reduced liver insulin signaling, whereas glucose upregulates ChREBP and triglyceride synthesis without impairing insulin signaling.

Understanding how different sugars affect your liver can help you make better choices. Fructose drives fat production and insulin resistance through specific genetic pathways (SREBP1c), while glucose may actually support insulin sensitivity. If you consume high-fat meals, minimizing fructose (soda, candy) is more critical for metabolic health than avoiding glucose sources.

Mitochondrial dysfunction, characterized by impaired oxidative capacity and increased reactive oxygen species (ROS), promotes insulin resistance in skeletal muscle by causing the accumulation of lipotoxic lipid intermediates (diacylglycerol and ceramide) that inhibit insulin signaling.

For those with insulin resistance or T2DM, focusing on interventions that support mitochondrial health (like exercise which upregulates PGC-1α) may be more effective than focusing solely on caloric restriction. The paper suggests that boosting mitochondrial function can improve insulin sensitivity, potentially by reducing toxic lipid buildup in muscles.

Obesity-induced adipose tissue hypertrophy triggers a proinflammatory state (via TNF-α, IL-6, MCP-1, and reduced adiponectin) that directly causes endothelial dysfunction by disrupting the balance of vasodilators (NO) and vasoconstrictors, initiating atherosclerosis and cardiovascular disease.

Excess body fat is not just stored energy; it acts as an active organ that releases inflammatory chemicals (like TNF-α and IL-6) and reduces protective ones (adiponectin). This chemical imbalance damages the inner lining of your blood vessels (endothelium), leading to stiffness, plaque buildup, and heart disease risk. Managing weight and inflammation is critical to protecting your vascular health.

Caloric restriction (CR) reprograms the single-cell transcriptional landscape of aging, altering gene expression patterns in specific tissues.

Caloric restriction changes how genes are expressed in cells, particularly in rats. This database allows researchers to see exactly which genes are affected, potentially leading to drugs that mimic these benefits without strict dieting.

Lymphocyte proportion in skeletal muscle is lower in young females compared to other demographic groups (young males, old males, old females).

Young women may have distinct immune cell profiles in muscle compared to men or older women. This does not change training advice but highlights biological differences in immune response.

In skeletal muscle, the accumulation of lipid intermediates such as diacylglycerol (DAG) and ceramides directly impairs insulin-stimulated glucose uptake by activating serine/threonine kinases that inhibit the insulin receptor substrate-1 (IRS-1).

If you have insulin resistance, simply reducing total body fat is the standard approach, but understanding that specific toxic lipid byproducts (like DAGs) are the direct cause helps explain why some lean individuals or athletes might have different metabolic profiles. Focus on improving metabolic flexibility through exercise, which helps clear these toxic intermediates.

Perilipin 2 (PLIN2) and Perilipin 5 (PLIN5) overexpression in skeletal muscle can protect against lipotoxicity and improve insulin signaling by sequestering fatty acids into lipid droplets, thereby reducing toxic lipid intermediates like DAG and ceramides.

Endurance training and metabolic health can upregulate protective proteins like PLIN5, which help store fatty acids safely in lipid droplets. This prevents them from turning into toxic byproducts that block insulin action. Prioritize exercises that improve metabolic flexibility.

DNA methylation-based epigenetic clocks serve as accurate biomarkers for predicting biological age, disease risk, and mortality, often outperforming traditional chronological age metrics.

Use epigenetic age as a diagnostic tool to assess your biological aging rate relative to your chronological age. While you cannot change your birth date, tracking these biomarkers (via blood tests) can help identify early risks for diseases like diabetes, cardiovascular issues, or cognitive decline, allowing for earlier lifestyle or medical interventions.

Specific DNA methylation alterations in blood (e.g., ABCG1, TXNIP, SLC30A8) can predict the onset of Type 2 Diabetes (T2D) prior to clinical diagnosis, offering a window for early detection.

If you have risk factors for Type 2 Diabetes (high BMI, family history), ask your doctor about emerging epigenetic biomarkers if available. While not yet standard of care, these tests may detect metabolic risk earlier than blood sugar tests, allowing for earlier lifestyle interventions.

Epigenetic age acceleration, measured by DNA methylation clocks, is associated with increased risk of Cardiovascular Disease (CVD) and mortality.

Maintain cardiovascular health through lifestyle choices (diet, exercise, no smoking) as these factors influence epigenetic aging. While you cannot change your chronological age, keeping your epigenetic age close to your chronological age is associated with lower CVD risk and longer life expectancy.

Targeting de novo lipogenesis (DNL) via ACC inhibitors (e.g., GS-0976, MK-4074) significantly reduces hepatic steatosis and DNL in patients with NASH.

ACC inhibitors like GS-0976 are being tested to directly reduce liver fat production. In trials, 20mg daily for 12 weeks reduced liver fat by 29%, significantly better than placebo. This is a pharmacological option for those who may not achieve sufficient weight loss through lifestyle alone.

Estrogen (17β-estradiol) improves insulin sensitivity and suppresses hepatic gluconeogenesis by activating the ERα-PI3K-Akt-Foxo1 signaling pathway, thereby reducing fasting blood glucose levels.

In preclinical models, estrogen improves blood sugar control by telling the liver to stop producing excess glucose. This happens through a specific signaling pathway involving ERα and Foxo1. This suggests that maintaining healthy estrogen levels or targeting this specific liver pathway could be a strategy for managing glucose metabolism, particularly in postmenopausal women or those with estrogen deficiency.

Obesity in older American adults is associated with a distinct gut microbiome taxonomic signature characterized by reduced species richness and specific shifts in bacterial abundance, including increased Bacilli (Streptococcaceae, Lactobacillaceae) and decreased Clostridia (Christensenellaceae, Clostridiaceae).

Your gut bacteria look different when you are obese, specifically with fewer diverse species and lower levels of certain beneficial bacteria like Christensenellaceae. While this doesn't tell you how to fix it directly, it suggests that restoring microbial diversity might be a valid area for dietary intervention, rather than focusing on simple 'good vs bad' bacteria ratios.

Obese visceral fat inflammation is an initially protective adaptive response to restore metabolic homeostasis, but becomes detrimental when structural damage and senescence trigger chronic immune infiltration.

Understand that inflammation in fat tissue is not just 'damage' but a complex signal. In the early stages of weight gain, it helps your body adapt to storing more energy. However, if this stress continues, the system breaks down, leading to structural damage and chronic disease. The goal is not to blindly suppress inflammation but to address the root cause: excess nutrient influx and adipocyte overload.

Adipocyte hypertrophy and subsequent endoplasmic reticulum stress trigger a pro-inflammatory response (metaflammation) that initially preserves metabolic control by promoting lipolysis and tissue remodeling.

As fat cells grow larger, they become stressed and send out signals to break down fat and remodel tissue. This is a natural attempt to manage excess energy. If this system works, you may remain metabolically healthy despite being overweight.

Chronic structural damage in visceral fat, characterized by adipocyte death and senescence, shifts inflammation from protective to detrimental by recruiting circulating immune cells and causing fibrosis.

When fat cells die or become senescent, they release signals that attract immune cells, leading to chronic inflammation and scarring (fibrosis). This is the stage where metabolic health typically declines.

SGLT-2 inhibitor monotherapy produces only moderate weight loss (1.5–2 kg) in obesity because it triggers counter-regulatory mechanisms that increase appetite and energy intake, offsetting the caloric deficit from glucosuria.

If you use an SGLT-2 inhibitor (like Jardiance or Farxiga) for weight loss, expect a modest drop of 1.5–2 kg. Your body will likely try to counteract this by making you hungrier. To get significant weight loss, this medication is rarely enough on its own; it works best when combined with drugs that suppress appetite (like GLP-1 agonists) or lifestyle changes that actively manage hunger.

The association between egg consumption and CVD/mortality is largely explained by the dietary cholesterol content within the eggs, as the association becomes non-significant when adjusting for total dietary cholesterol.

If you eat eggs, be mindful of your total dietary cholesterol intake. The risk associated with eggs appears to come from their cholesterol content, so balancing egg intake with other cholesterol-containing foods is key to managing CVD risk.

Genetic variants associated with restless legs syndrome (RLS) also influence sleep duration, quality, and timing.

If you have RLS, addressing it may improve overall sleep metrics.